Cue Biopharma Past Earnings Performance
Past criteria checks 0/6
Cue Biopharma's earnings have been declining at an average annual rate of -5.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 10% per year.
Key information
-5.3%
Earnings growth rate
10.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 10.0% |
| Return on equity | -175.9% |
| Net Margin | -468.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cue Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10 | -45 | 18 | 0 |
| 30 Jun 24 | 8 | -47 | 19 | 0 |
| 31 Mar 24 | 7 | -50 | 19 | 0 |
| 31 Dec 23 | 5 | -51 | 19 | 0 |
| 30 Sep 23 | 4 | -52 | 22 | 0 |
| 30 Jun 23 | 2 | -52 | 19 | 0 |
| 31 Mar 23 | 0 | -52 | 18 | 0 |
| 31 Dec 22 | 1 | -53 | 19 | 0 |
| 30 Sep 22 | 9 | -47 | 17 | 0 |
| 30 Jun 22 | 12 | -49 | 18 | 0 |
| 31 Mar 22 | 14 | -46 | 18 | 0 |
| 31 Dec 21 | 15 | -44 | 17 | 0 |
| 30 Sep 21 | 7 | -47 | 16 | 0 |
| 30 Jun 21 | 5 | -44 | 15 | 0 |
| 31 Mar 21 | 4 | -44 | 15 | 0 |
| 31 Dec 20 | 3 | -45 | 15 | 0 |
| 30 Sep 20 | 4 | -43 | 14 | 0 |
| 30 Jun 20 | 4 | -40 | 14 | 0 |
| 31 Mar 20 | 4 | -38 | 13 | 0 |
| 31 Dec 19 | 3 | -37 | 13 | 0 |
| 30 Sep 19 | 3 | -39 | 14 | 0 |
| 30 Jun 19 | 2 | -45 | 14 | 0 |
| 31 Mar 19 | 2 | -43 | 13 | 0 |
| 31 Dec 18 | 1 | -39 | 11 | 0 |
| 30 Sep 18 | 1 | -38 | 8 | 0 |
| 30 Jun 18 | 0 | -30 | 6 | 0 |
| 31 Mar 18 | 0 | -27 | 5 | -2 |
| 31 Dec 17 | 0 | -23 | 4 | 0 |
| 30 Sep 17 | 0 | -16 | 4 | 2 |
| 30 Jun 17 | 0 | -13 | 4 | 3 |
| 31 Mar 17 | 0 | -10 | 4 | 6 |
| 31 Dec 16 | 0 | -8 | 3 | 5 |
Quality Earnings: 1UC is currently unprofitable.
Growing Profit Margin: 1UC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1UC is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.
Accelerating Growth: Unable to compare 1UC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1UC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 1UC has a negative Return on Equity (-175.87%), as it is currently unprofitable.